BridgeBio Oncology Therapeutics (BBOT) EPS (Basic) (2024 - 2026)

BridgeBio Oncology Therapeutics has reported EPS (Basic) for 3 years, with the latest figure at -$775.78 in Q1 2026.

• Quarterly EPS (Basic) fell 3741806.33% year-over-year to -$775.78 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2912.7 (down 11196554.95% YoY) and the FY2025 annual result came in at -$7.48, down 7754.68% from the prior year.
• EPS (Basic) declined to -$775.78 in Q1 2026 per BBOT's latest filing, from -$2.77 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.1 in Q3 2024 and troughed at -$775.78 in Q1 2026.
• A 3-year average of -$86.71 and a median of -$0.02 in 2025 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2025 and 2026: EPS (Basic) tumbled 89.9% in 2025, then plunged 3741806.33% in 2026.
• Over 3 years, EPS (Basic) stood at -$0.17 in 2024, then sank by 1560.32% to -$2.77 in 2025, then plunged by 27936.3% to -$775.78 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$775.78, -$2.77, and -$1.95 for Q1 2026, Q4 2025, and Q3 2025 respectively.